Cargando…
Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
OBJECTIVE: To assess the efficacy of the Diabetes Medication Choice Decision Aid among patients with type 2 diabetes in Greece. DESIGN: Open-label cluster randomised controlled trial. SETTING: Primary and secondary care practices across Greece. PARTICIPANTS: 5 sites allocated to the decision aid (n=...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129072/ https://www.ncbi.nlm.nih.gov/pubmed/28186933 http://dx.doi.org/10.1136/bmjopen-2016-012185 |
_version_ | 1782470527694143488 |
---|---|
author | Karagiannis, Thomas Liakos, Aris Branda, Megan E Athanasiadou, Eleni Mainou, Maria Boura, Panagiota Goulis, Dimitrios G LeBlanc, Annie Montori, Victor M Tsapas, Apostolos |
author_facet | Karagiannis, Thomas Liakos, Aris Branda, Megan E Athanasiadou, Eleni Mainou, Maria Boura, Panagiota Goulis, Dimitrios G LeBlanc, Annie Montori, Victor M Tsapas, Apostolos |
author_sort | Karagiannis, Thomas |
collection | PubMed |
description | OBJECTIVE: To assess the efficacy of the Diabetes Medication Choice Decision Aid among patients with type 2 diabetes in Greece. DESIGN: Open-label cluster randomised controlled trial. SETTING: Primary and secondary care practices across Greece. PARTICIPANTS: 5 sites allocated to the decision aid (n=101 patients) and 4 sites to control (n=103 patients). INTERVENTION: Clinicians and patients in the intervention arm used a decision aid, based on outcomes that both consider important when choosing among antihyperglycaemic medications. Patients in the control arm received usual care. OUTCOME MEASURES: The primary outcome was patient's level of decisional comfort after the initial clinical encounter. Secondary outcomes included patient's knowledge about type 2 diabetes and medications, and patient's and clinician's satisfaction. Adherence to prescribed antihyperglycaemic medication and change in glycated haemoglobin were assessed at 24 weeks. RESULTS: Patients in both arms had similar scores in overall decisional comfort (mean difference between the usual care and decision aid arms −6.9, 95% CI −21.5 to 7.7) and its subscales. Patients' knowledge was high in both arms (mean difference 2.3%, 95% CI −15.7% to 20.4%). Patients and clinicians in both groups were equally satisfied with the decision-making. No significant difference in medication adherence and glycaemic control was found across arms. Clinicians found the decision aid useful and reported that its integration in their daily routine was easy. CONCLUSIONS: The decision aid was implemented and positively received in the clinical setting in Greece, in line with the patient-centred approach endorsed by current guidelines. However, this trial yielded imprecise results in terms of patient outcomes. Further research is needed to investigate the interaction between the patient and the clinician in order to clarify the association between the use of decision aids and implementation of shared decision-making. TRIAL REGISTRATION NUMBER: NCT01861756. Pre-results. |
format | Online Article Text |
id | pubmed-5129072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51290722016-12-02 Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial Karagiannis, Thomas Liakos, Aris Branda, Megan E Athanasiadou, Eleni Mainou, Maria Boura, Panagiota Goulis, Dimitrios G LeBlanc, Annie Montori, Victor M Tsapas, Apostolos BMJ Open Diabetes and Endocrinology OBJECTIVE: To assess the efficacy of the Diabetes Medication Choice Decision Aid among patients with type 2 diabetes in Greece. DESIGN: Open-label cluster randomised controlled trial. SETTING: Primary and secondary care practices across Greece. PARTICIPANTS: 5 sites allocated to the decision aid (n=101 patients) and 4 sites to control (n=103 patients). INTERVENTION: Clinicians and patients in the intervention arm used a decision aid, based on outcomes that both consider important when choosing among antihyperglycaemic medications. Patients in the control arm received usual care. OUTCOME MEASURES: The primary outcome was patient's level of decisional comfort after the initial clinical encounter. Secondary outcomes included patient's knowledge about type 2 diabetes and medications, and patient's and clinician's satisfaction. Adherence to prescribed antihyperglycaemic medication and change in glycated haemoglobin were assessed at 24 weeks. RESULTS: Patients in both arms had similar scores in overall decisional comfort (mean difference between the usual care and decision aid arms −6.9, 95% CI −21.5 to 7.7) and its subscales. Patients' knowledge was high in both arms (mean difference 2.3%, 95% CI −15.7% to 20.4%). Patients and clinicians in both groups were equally satisfied with the decision-making. No significant difference in medication adherence and glycaemic control was found across arms. Clinicians found the decision aid useful and reported that its integration in their daily routine was easy. CONCLUSIONS: The decision aid was implemented and positively received in the clinical setting in Greece, in line with the patient-centred approach endorsed by current guidelines. However, this trial yielded imprecise results in terms of patient outcomes. Further research is needed to investigate the interaction between the patient and the clinician in order to clarify the association between the use of decision aids and implementation of shared decision-making. TRIAL REGISTRATION NUMBER: NCT01861756. Pre-results. BMJ Publishing Group 2016-11-14 /pmc/articles/PMC5129072/ /pubmed/28186933 http://dx.doi.org/10.1136/bmjopen-2016-012185 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Diabetes and Endocrinology Karagiannis, Thomas Liakos, Aris Branda, Megan E Athanasiadou, Eleni Mainou, Maria Boura, Panagiota Goulis, Dimitrios G LeBlanc, Annie Montori, Victor M Tsapas, Apostolos Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial |
title | Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial |
title_full | Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial |
title_fullStr | Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial |
title_full_unstemmed | Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial |
title_short | Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial |
title_sort | use of the diabetes medication choice decision aid in patients with type 2 diabetes in greece: a cluster randomised trial |
topic | Diabetes and Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129072/ https://www.ncbi.nlm.nih.gov/pubmed/28186933 http://dx.doi.org/10.1136/bmjopen-2016-012185 |
work_keys_str_mv | AT karagiannisthomas useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT liakosaris useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT brandamegane useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT athanasiadoueleni useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT mainoumaria useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT bourapanagiota useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT goulisdimitriosg useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT leblancannie useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT montorivictorm useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial AT tsapasapostolos useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial |